![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: We sought to determine the psoriatic nail feature which responds to ustekinumab treatment more effectively, and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis.
Methods: Thirty patients with moderate-to-severe plaque psoriasis were prospectively enrolled and treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs.
Results: Of the 30 patients, 13 (43.3%) had fingernail psoriasis present at baseline. Mean NAPSI scores improved from 9.46 ± 8.7 at baseline to 6.00 ± 5.2 at week 52, but the improvement was not statistically significant (p = .09). Mean N-NAIL scores significantly improved from 5.46 ± 5.1 at baseline to 3.92 ± 3.7 at week 52 (p = .04). Of the psoriatic nail features, only the splinter hemorrhages significantly improved at week 52 compared to baseline.
Conclusions: When comparing the mean scores between week 0 and 52, the N-NAIL score (p = .04) better reflected a significant improvement of nail psoriasis than the NAPSI (p = .09), and ustekinumab treatment resulted in a more rapid and effective improvement of splinter hemorrhages.
Acknowledgments
The authors thank the staff of the Medical Research Collaborating Center at the Seoul National University Bundang Hospital for performing the statistical analyses.
Disclosure statement
Dr. Youn has served as an advisor, received speaker honoraria and participated in clinical trials for AbbVie, CKD-pharma, Elli-Lilly, Janssen, and Novartis. He participated in a clinical trial for Kyowa-Kirin. He also served as an advisor for Celgene.